You are here:

Archived: etravirine (Intelence)

Advice

Following a full submission

etravirine (Intelence), in combination with a boosted protease inhibitor and other antiretroviral medicinal products, is not recommended for use within NHS Scotland for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients.

In HIV-1 infected adults with resistance to currently available non-nucleoside reverse transcriptase inhibitors (NNRTIs) and at least three primary protease inhibitor (PI) mutations who were receiving an optimised background regimen that included boosted darunavir, nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and optional enfuvirtide, etravirine produced significant improvements in virological, immunological and clinical outcomes when compared with placebo.

The manufacturer’s justification of the treatment’s cost in relation to its health benefits was not sufficient to gain acceptance by SMC. The licence holder has indicated their intention to resubmit

Drug Details

Drug Name: etravirine (Intelence)
SMC Drug ID: 530/09
Manufacturer: Tibotec (Janssen-Cilag Ltd)
Indication: Treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients
BNF Category:
Sub Category: 5.3 Antiviral Drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 9 February 2009

Current Advice

Resubmission 10 August 2009

Back